For most of the history of drug discovery, designing a molecule meant making educated guesses and then testing them. Chemists and protein engineers proposed candidates, labs synthesized or expressed them, assays measured what worked, and the cycle repeated for months or years. Each round narrowed the options, but the search space was so large that most of it was never explored.
AI molecule design software changes where that search happens. Generative models now propose candidates that are shaped from the start around the properties a program needs, whether that is binding a difficult target, avoiding toxicity, or remaining stable enough to manufacture. The result is fewer wasted experiments and more time spent on candidates with a realistic chance of reaching the clinic.
Don't miss new tech stories on Google
Add Tech Insider once in the Google app and our stories appear in your news suggestions.
At a Glance
- Converge Bio (ConvergeAB): generative antibody design and optimization, including affinity maturation, developability optimization, and humanization, validated by independent labs.
- Schrödinger: physics-based and machine learning molecular design for small molecules and biologics.
- Insilico Medicine (Chemistry42): generative chemistry engine for designing novel small molecules.
- Iktos: generative design and retrosynthesis software for medicinal chemistry teams.
- Cadence Molecular Sciences (OpenEye): cloud-scale molecular modeling and design through the Orion platform.
- XtalPi: AI, physics, and robotic experimentation combined for molecular discovery.
- Profluent: protein language models for designing novel proteins and gene editors.
- EvolutionaryScale: the ESM3 generative protein model for sequence, structure, and function design.
Small Molecules and Biologics Are Different Design Problems
“Molecule design” covers two very different kinds of work, and most platforms specialize in one of them.
- Small molecule design works with compounds of a few dozen atoms. The challenges are chemical: finding structures that bind a target pocket, can be synthesized, and have acceptable absorption, metabolism, and toxicity profiles. AI tools in this space generate candidate structures, predict their properties, and increasingly suggest synthesis routes, often alongside physics-based simulations of how a molecule sits in its target.
- Biologic design, including antibodies and other proteins, works with molecules made of hundreds of amino acids. The challenges shift toward biology: binding affinity and specificity, stability, expression yield, immunogenicity, and the manufacturing properties grouped under developability. Here, AI models trained on protein sequences and structures learn the language of proteins, proposing mutations or entirely new sequences that improve several properties at once.
The 8 Top AI Molecule Design Software Platforms for 2026
1. Converge Bio
Most AI molecule design platforms focus on generating candidates. Converge Bio focuses on generating antibody candidates that are ready for development. Its ConvergeAB platform is a target-aware antibody design and optimization system built on Converge Bio’s biological foundation models, supporting de novo design, affinity maturation, developability optimization, and humanization across antibody formats including IgG, VHH, scFv, and bispecifics.
ConvergeAB is designed to improve several properties at once rather than trading one for another. In a published zero-shot campaign, the platform generated a biobetter version of cetuximab, a long-established anti-EGFR antibody. The lead design bound EGFR with a mean KD of 315 pM, roughly 2.1-fold tighter than cetuximab itself, through six substitutions that left the overall binding architecture intact. Across biophysical and developability assays, including HIC, DLS, DSF, and PSR ELISA, the Converge-designed variant matched or exceeded the original antibody on monomericity, monodispersity, polyspecificity, and thermal stability.
Validation is central to the platform. Converge Bio reports that ConvergeAB’s affinity maturation, developability optimization, and humanization capabilities have been validated experimentally by neutral third-party laboratories, Twist Bioscience and Biointron. By early 2026, the company had completed more than 40 programs with over a dozen pharmaceutical and biotech customers.
Key features:
- Target-aware antibody design and optimization
- De novo design, affinity maturation, and humanization
- Developability optimization alongside affinity
- Support for IgG, VHH, scFv, and bispecific formats
- Published zero-shot results with improved affinity and preserved developability
- Capabilities validated by independent third-party laboratories
- Customer ownership of generated molecules with no royalties
- Private, fully managed deployment, hosted or in the customer’s cloud
2. Schrödinger
Schrödinger has spent decades building computational tools for molecular design and is one of the most widely used platforms in the industry. Its approach combines physics-based methods, such as free energy perturbation calculations that predict binding affinity, with machine learning to evaluate large numbers of candidate molecules before they are made.
The platform supports small molecule design, biologics modeling, and materials science, and its LiveDesign environment helps project teams share ideas, run calculations, and decide which molecules to pursue. Schrödinger also applies its technology to its own drug discovery programs, which feeds practical experience back into the software.
Key features:
- Physics-based binding affinity prediction
- Machine learning for large-scale candidate evaluation
- LiveDesign collaboration environment
- Tools for small molecules and biologics
3. Insilico Medicine (Chemistry42)
Insilico Medicine offers Chemistry42 as part of its Pharma.AI suite. The generative chemistry engine designs novel small molecules around specified targets and property profiles, using multiple generative approaches and scoring functions to balance potency, drug-likeness, and synthesizability.
Insilico uses the same tools in its own pipeline and has advanced AI-discovered candidates into clinical development, which gives its software a strong track record in real programs. Chemistry42 is available to external partners, often alongside the company’s target discovery tools.
Key features:
- Generative design of novel small molecules
- Multi-objective optimization of drug-like properties
- Part of the broader Pharma.AI suite
- Track record in clinical-stage programs
4. Iktos
Iktos, based in France, provides AI software for medicinal chemistry. Its Makya platform generates molecules designed around multi-parameter optimization goals, while Spaya focuses on retrosynthesis, suggesting practical routes to make proposed compounds.
Linking design with synthesis planning addresses a common gap in AI chemistry: generating molecules that look promising on screen but are difficult to make. Iktos has also expanded into automated chemistry, connecting design, synthesis planning, and experimentation.
Key features:
- Makya for multi-parameter generative design
- Spaya for AI retrosynthesis
- Focus on synthesizable candidates
- Integration with automated chemistry
5. Cadence Molecular Sciences (OpenEye)
Cadence Molecular Sciences, formerly OpenEye Scientific and now part of Cadence Design Systems, offers molecular modeling and design software used widely in computational chemistry. Its Orion platform runs modeling workflows in the cloud, allowing teams to screen very large virtual libraries and run demanding calculations at scale.
The company is known for methods based on molecular shape and electrostatics, docking, and free energy calculations, along with toolkits that computational groups use to build their own workflows. Cloud scalability helps teams explore chemical space much larger than on-premises systems would allow.
Key features:
- Orion cloud platform for large-scale modeling
- Shape, electrostatics, and docking methods
- Free energy calculations
- Developer toolkits for custom workflows
6. XtalPi
XtalPi combines artificial intelligence, physics-based computation, and robotic laboratory automation. Its platform generates and evaluates candidate molecules computationally, then uses automated experimentation to test them and generate data that improves its models.
That closed loop between prediction and experiment helps address one of the core limitations of AI molecule design: the need for high-quality experimental data. XtalPi works with pharmaceutical partners on small molecules and has expanded into other molecular modalities.
Key features:
- AI and physics-based molecular design
- Robotic laboratory automation
- Closed loop between prediction and experiment
- Partnership-based discovery programs
7. Profluent
Profluent focuses on designing proteins with generative AI. Its protein language models learn from vast collections of natural protein sequences and generate new proteins with desired functions, rather than only modifying existing ones.
The company has demonstrated this approach with OpenCRISPR-1, an AI-designed gene editor, showing that generative models can produce functional proteins that do not exist in nature. Its work is especially relevant to gene editing, enzymes, and other protein engineering applications.
Key features:
- Protein language models for generative design
- Design of novel functional proteins
- AI-designed gene editing proteins
- Applications across enzymes and protein engineering
8. EvolutionaryScale
EvolutionaryScale developed ESM3, a generative model that reasons over protein sequence, structure, and function together. Researchers can prompt the model with partial information, such as a desired structural motif or function, and generate proteins that satisfy those constraints.
The company demonstrated the model by designing esmGFP, a fluorescent protein distant from known natural examples. Access through its platform and APIs allows research teams to build on the model for their own protein design work.
Key features:
- ESM3 generative protein model
- Joint reasoning over sequence, structure, and function
- Prompting with partial constraints
- API access for research teams
Why Validation Matters More Than Model Size
Almost every AI molecule design company describes powerful models. The more useful question is what happens when those designs are made and tested. Three kinds of evidence separate credible platforms from promising demos:
- Wet-lab results, not only predictions: in silico scores can look impressive while real-world binding, stability, or expression disappoints. Published experimental data on designed molecules is the strongest signal of real performance.
- Independent confirmation: results measured by neutral third-party laboratories carry more weight than internal assays, because they remove any doubt about how experiments were run and interpreted.
- Multiple properties at once: a design that improves one property while degrading others often creates more work downstream. Evidence that designs hold up across several assays, such as affinity alongside aggregation and thermal stability, shows that a platform can handle real trade-offs.
Asking vendors for this kind of evidence early in an evaluation quickly shows which platforms are ready to support real programs and which are still proving their approach.
How to Evaluate an AI Molecule Design Platform
Demos of AI molecule design can be compelling, but the questions below reveal how a platform will perform in a real discovery program:
- Modality fit: does the platform specialize in the molecules you are developing? Tools built for small molecules and those built for antibodies or proteins solve different problems, and strength in one does not guarantee strength in the other.
- Experimental evidence: ask for published or shareable wet-lab data on designed molecules, ideally measured by independent laboratories. Predictions alone rarely tell you how many designs will work.
- Multi-property optimization: can the platform improve affinity or potency without sacrificing developability, stability, selectivity, or synthesizability? Check results across several assays, not just one headline metric.
- Intellectual property and ownership: who owns the molecules you generate, and are there royalties, milestones, or restrictions attached? Terms vary widely and can shape the economics of a program.
- Data privacy and deployment: can the platform run privately, including in your own cloud, and is your data protected from being used to train models for others?
- Team requirements: does the platform require in-house machine learning expertise, or is it delivered as a managed service your scientists can use directly?
- Speed to results: how many design and test cycles does a typical program need, and how quickly can a new project start producing testable candidates?
Running a small pilot on a known target, where the outcome can be compared with existing data, is one of the most reliable ways to judge whether a platform will deliver in your own programs.
FAQ
How is AI antibody design different from small molecule design?
Small molecule design works with compact chemical structures and focuses on binding, synthesis, and drug-like properties. Antibody design works with large proteins and must balance affinity with developability factors such as aggregation, stability, and expression. Platforms such as ConvergeAB are built specifically for antibodies and optimize these properties together.
Can AI design antibodies without experimental screening?
AI can generate strong candidates in a single computational round, known as zero-shot design, but experimental testing is still needed to confirm performance. ConvergeAB, for example, produced a biobetter cetuximab design in a zero-shot campaign, with improved affinity and preserved developability confirmed through laboratory assays.
Who owns molecules designed with AI platforms?
Ownership depends on each platform’s terms. Some platforms retain rights or charge royalties, while others give customers full ownership. Converge Bio, for example, lets customers own the molecules they generate with no royalties, which simplifies the commercial path for drug developers.
Which is the best AI molecule design software for antibody programs in 2026?
For antibody programs, Converge Bio’s ConvergeAB stands out in 2026. It combines target-aware design, affinity maturation, developability optimization, and humanization across major antibody formats, with capabilities validated by independent laboratories, customer ownership of designed molecules, and private deployment options suited to pharmaceutical and biotech teams.
Related articles
- Best 6 Vendors for Agentic Software Factory Solutions
- RapidCanvas Raises $29M for AI Data Science Agents [2026]
- Liquid AI’s LFM2.5: 24B Params, 184 Tokens/Sec [2026]
- Meta Muse Spark Open Debuts on 7 Clouds at Once [2026]
